Drawing for BUILD FOR BREAKTHROUGH

USPTO serial 99709354

BUILD FOR BREAKTHROUGH

Reviewed by CopyMark Law Group

Status 641Office Action
Filing date
Status date
Registration date
—
Examiner
MILLER, CHARLES FREDERICK
Law office
TMO LAW OFFICE 112

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 641: Status 641 means the USPTO mailed a non-final Office Action identifying issues with your application. You typically have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.

Need help with BUILD FOR BREAKTHROUGH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lori P. Hager

88 S Finley Avenue 2nd Fl. Suite ABasking Ridge, NJ 07920United States

Goods and services

ClassDescriptionStatusFirst use
035Advertising agencies specializing in marketing strategies to promote businesses; Advertising and marketing consultancy; Advertising and publicity services, namely, promoting the goods, services, brand identity and commercial information and news of third parties through digital technology, video and live events; Advertising consultation; Advertising services in the field of pharmaceuticals; Advertising services, namely, creating corporate and brand identity for others; Advertising services, namely, promoting and marketing the goods and services of others in the field of pharmaceuticals via print and electronic media; Brand concept and brand development services for corporate clients; Business consultation in the field of pharmaceuticals; Concept and brand development services for corporate clients; Conducting market surveys; Digital advertising services; Market analysis and research services; Marketing consultation in the field of pharmaceuticals; Marketing consulting; Marketing plan development; Providing advertising, marketing and promotional services for the pharmaceutical and medical industry; Providing advertising, marketing and promotional services for the pharmaceutical and medical products of others; Business consulting services relating to the integration of the areas of business process technology, organizational learning, change management, and operational sustainability; Computerized database management; Management and compilation of computerised databases; Business management and consultation in the field of pharmaceuticals; Business advisory services in the field of pharmaceuticals; Business strategic planning services in the field of marketing services and data analysis, in the pharmaceutical industry; Business assistance, management and information services; Information, advisory and consultancy services relating to business and management or business administration, including such services provided on line or via the internet; Consultancy and advisory services in the field of business strategy; Business management consulting and advisory services for the pharmaceutical industry; Business consulting services in the field of business management, workflow and quality in the pharmaceutical industry; Business administration services in the field of pharmaceuticals; Data processing services in the field of pharmaceuticals; Marketing services, namely, consumer marketing research; Marketing forecasting; Marketing services rendered using artificial intelligence (AI); Providing business management information in connection with consulting and advisory services in the field of strategic planning; Business advisory services in the field of pharmaceuticals, namely providing descriptive and predictive analytics; Business advisory services in the field of pharmaceuticals, namely providing formulation of best practices for the pharmaceuticals industry; Preparation of business reports; Business management consultancy servicesACTIVE—
036Strategic corporate financial advisory services; Information, advisory, consultancy and financial research services relating to finance and investments; Financial advisory services; Financial advisory and consultancy services, namely, strategic corporate financial advisory, and investments advisory services; Financial advisory and consultancy services, namely, services related to financial profiles; Financial advisory and consultancy services, namely, financial revenue forecastsACTIVE—
042Providing on-line non-downloadable software for predictive analytics in the field of pharmaceuticals; Providing on-line non-downloadable software for managing, accessing and sharing information and data related to performance metrics; Providing on-line non-downloadable software for analyze and select of algorithms for use in predictive analytics in the field of pharmaceuticals; Providing on-line non-downloadable software for creating advertising layout; Providing on-line non-downloadable software for compiling and organizing business intelligence; Software as a service (SAAS) services, namely, hosting software for use by others for use by others for business data analysis, in the field of pharmaceuticals; Software as a service (SAAS) services, namely, hosting software for use by others for use by others for tracking performance metrics, data visualizations, and predictive analytics in the field of pharmaceuticals, and providing reports; Software as a service (SAAS) services featuring software for tracking performance metrics, data visualizations, and predictive analytics in the field of pharmaceuticals, and providing reports; Software as a service (SAAS) services featuring software for use in managing, developing, analyzing, summarizing, editing, and sorting data stored in computer database; Software as a service (SAAS) services featuring software for business data analysis, in the field of pharmaceuticals; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for managing, developing, analyzing, summarizing, editing, and sorting data stored in computer databases in the field of pharmaceuticals; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for generating business analysis reports; Platform as a service (PAAS) featuring computer software platforms for tracking performance metrics, data visualizations, and predictive analytics in the field of pharmaceuticals and providing reports and alerts concerning such performance; Platform as a service (PAAS) featuring computer software platforms for information processing, namely, software for managing, developing, analyzing, summarizing, editing, and sorting data stored in computer databases; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for tracking performance metrics, data visualizations, and predictive analytics in the field of pharmaceuticals, and providing reports; Computer services in the nature of customized web pages and other data feed formats featuring user-defined information; Platform as a service (PAAS) featuring computer software platforms for business data analysis and predictive analytics, in the field of pharmaceuticalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 1, 2026XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Oct 1, 2026XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Jul 2, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 2, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 2, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 29, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 29, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 29, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 23, 2026DOCKASSIGNED TO EXAMINER—
May 21, 2026TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
May 21, 2026PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Mar 18, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 18, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 18, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance